Sana Biotechnology
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 328
- Market Cap
- $1.2B
- Website
- http://www.sana.com
- Introduction
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.
Study Evaluating SC291 in Subjects with Severe R/r B-cell Mediated Autoimmune Diseases (GLEAM)
- Conditions
- Lupus ErythematosusSystemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisSLE (Systemic Lupus)Granulomatous PolyangiitisMicroscopic Polyangiitis
- Interventions
- Biological: SC291
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Sana Biotechnology
- Target Recruit Count
- 36
- Registration Number
- NCT06294236
- Locations
- ๐บ๐ธ
Emory University, Atlanta, Georgia, United States
๐บ๐ธUniversity of Colorado, Aurora, Colorado, United States
๐บ๐ธJohns Hopkins Hospital, Baltimore, Maryland, United States
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
- Conditions
- Large B-cell LymphomaNon Hodgkin's Lymphoma
- Interventions
- Drug: SC262
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Sana Biotechnology
- Target Recruit Count
- 35
- Registration Number
- NCT06285422
- Locations
- ๐บ๐ธ
The University of Kansas Hospital, Kansas City, Kansas, United States
๐บ๐ธSwedish Cancer Institute, Seattle, Washington, United States
๐บ๐ธFred Hutchinson Cancer Center, Seattle, Washington, United States
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
- Conditions
- Non Hodgkin LymphomaChronic Lymphocytic Leukemia
- Interventions
- Drug: SC291
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Sana Biotechnology
- Target Recruit Count
- 16
- Registration Number
- NCT05878184
- Locations
- ๐บ๐ธ
City of Hope, Duarte, California, United States
๐บ๐ธStanford Cancer Institute, Palo Alto, California, United States
๐บ๐ธNorthside Hospital, Atlanta, Georgia, United States